About GLP-1 Observer

Weekly tracking of GLP-1 and related clinical trials and company announcements so you don’t miss what matters.

Who it’s for

Biotech operators, investors, clinicians, and anyone who follows the GLP-1/incretin landscape and wants to stay current without spending hours searching.

What we cover (version 1.0)

• Newly registered clinical trials across all GLP-1 mechanisms

• Company announcements and press releases

• Mechanism deep dives and trial spotlights

This is version 1 - we’ll expand based on what you need most.

Why this exists

The GLP-1 / incretin landscape is moving fast. There are many trials (we’re tracking hundreds), drugs with new mechanisms of action, label expansions, supply and manufacturing updates, and a growing cast of competitors. GLP-1 Observer saves you time in keeping current. All material is cited so you can dive deeper when you want to.

Help us evolve

What would make this indispensable for you?

• Updates on conference presentations and data readouts

• Readouts on social media GLP-1 discussion

• Reporting on other clinical trial changes and information

• Pipeline comparisons and dashboards

• Something else entirely?

Reply to any email or comment - we’re very interested in your feedback and thoughts on what would make this useful for you.

Why it’s free

The newsletter will remain free. We want to learn from readers and refine coverage. Long-term, we may add paid tools (e.g., a trials dashboard with analytics), but this weekly brief stays our foundation.

Who’s Behind It

Michael Parker, MD / computer scientist. Former Harvard Medical School faculty; founded and led HMX, an online learning product used widely in biotech and pharma. Now focused on building tools that help the biotech community keep up with fast-moving developments—starting with the GLP-1 landscape.

LinkedIn · Contact: glp1observer@substack.com (or reply to any email)